Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Sci Rep ; 10(1): 13994, 2020 08 19.
Artículo en Inglés | MEDLINE | ID: mdl-32814782

RESUMEN

To propose a new test to evaluate the autonomic nervous system in patients with syncope: Multimodal Monitoring for Diagnosis of Dysautonomia (MMDD). We included 21 patients with syncope (16 female, 6 male, mean age 43.5 years) and 21 with no-syncope subjects (15 female, 7 male, mean age 45.1 years) to perform a test of nine 2-min stages: four while resting and four during active testing of autonomic response. Transcranial-Doppler, electrocardiogram, and photoplethysmography blood pressure pulse-to-pulse monitoring, allow registering six variables from the Middle Cerebral Artery and four from the Cardiovascular System. We analyze each variable's mean differences in each stage and its change when they pass from one stage to another with the T and Z tests. To understand the significance of the change, we use a logistic regression model for a certain subgroup of variables. Since we have a small dataset, we use the bootstrap technique to infer the general behavior that characterizes a syncope. Our data confirm differences between syncope and non-syncope patients during MMDD stress stages 2, 4, 6 and 8. Bootstrap and multivariate logistic regression allow us to identify which sets of variables in each of these stages of the MMDD are sufficiently sensitive to recognizing syncope. MMDD protocol can recognize a syncope patient with some confidence by detecting subtle changes in the autonomic nervous system. This protocol encourages us to continue to study the effectiveness of MMDD protocol allowing a new approach to future research.


Asunto(s)
Sistema Nervioso Autónomo/fisiopatología , Presión Sanguínea/fisiología , Sistema Cardiovascular/fisiopatología , Disautonomías Primarias/fisiopatología , Síncope/fisiopatología , Adulto , Sistema Nervioso Autónomo/diagnóstico por imagen , Sistema Cardiovascular/diagnóstico por imagen , Electrocardiografía/métodos , Estudios de Factibilidad , Femenino , Frecuencia Cardíaca/fisiología , Humanos , Masculino , Persona de Mediana Edad , Disautonomías Primarias/diagnóstico , Disautonomías Primarias/diagnóstico por imagen , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Síncope/diagnóstico , Síncope/diagnóstico por imagen , Ultrasonografía Doppler Transcraneal/métodos
2.
Math Med Biol ; 24(1): 35-56, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17060491

RESUMEN

Mathematical models for the population dynamics of de novo resistant Mycobacterium tuberculosis within individuals are studied. The models address the use of one or two antimicrobial drugs for treating latent tuberculosis (TB). They consider the effect of varying individual immune response strength on the dynamics for the appearance of resistant bacteria. From the analysis of the models, equilibria and local stabilities are determined. For assessing temporal dynamics and global stability for sensitive and drug-resistant bacteria, numerical simulations are used. Results indicate that for a low bacteria load that is characteristic of latent TB and for small reduction in an immune response, the use of a single drug is capable of curing the infection before the appearance of drug resistance. However, for severe immune deficiency, the use of two drugs will provide a larger time period before the emergence of resistance. Therefore, in this case, two-drugs treatment will be more efficient in controlling the infection.


Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Microbiana , Modelos Biológicos , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Pulmonar/microbiología , Algoritmos , Antibacterianos/uso terapéutico , Simulación por Computador , Quimioterapia Combinada , Granuloma/tratamiento farmacológico , Granuloma/microbiología , Humanos , Isoniazida/farmacología , Isoniazida/uso terapéutico , Mycobacterium tuberculosis/crecimiento & desarrollo , Rifampin/farmacología , Rifampin/uso terapéutico , Tuberculosis Pulmonar/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA